Shoaf, M. L., Gromeier, M., Brown, M. C., Buckley, E. D., Herndon II, J. E., Batich, K., … Desjardins, A. (2025). TIP-25. Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results. In Neuro-Oncology (Vol. 27, pp. v426–v426). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noaf201.1685

Shoaf, Madison L., Matthias Gromeier, Michael C. Brown, Evan D. Buckley, James E. Herndon II, Kristen Batich, Margaret O. Johnson, et al. “TIP-25. Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results.” In Neuro-Oncology, 27:v426–v426. Oxford University Press (OUP), 2025. https://doi.org/10.1093/neuonc/noaf201.1685.

Shoaf ML, Gromeier M, Brown MC, Buckley ED, Herndon II JE, Batich K, et al. TIP-25. Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results. In: Neuro-Oncology. Oxford University Press (OUP); 2025. p. v426–v426.

Shoaf, Madison L., et al. “TIP-25. Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results.” Neuro-Oncology, vol. 27, no. Supplement_5, Oxford University Press (OUP), 2025, pp. v426–v426. Crossref, doi:10.1093/neuonc/noaf201.1685.

Shoaf ML, Gromeier M, Brown MC, Buckley ED, Herndon II JE, Batich K, Johnson MO, Khasraw M, Low JT, Peters KB, Friedman AH, Friedman HS, Ashley DM, Bigner DD, Desjardins A. TIP-25. Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results. Neuro-Oncology. Oxford University Press (OUP); 2025. p. v426–v426.